Emily Barker Selected Research

Melanoma (Melanoma, Malignant)

10/2018

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emily Barker Research Topics

Disease

3	Infections 01/2023 - 03/2011
2	Retained Placenta 01/2023 - 01/2023
2	Hemorrhage 01/2023 - 01/2023
1	Congenital Abnormalities (Deformity) 01/2023
1	Premature Obstetric Labor (Premature Labor) 01/2023
1	Uterine Rupture 01/2023
1	Catel Manzke syndrome 01/2023
1	Neoplasms (Cancer) 01/2020
1	Melanoma (Melanoma, Malignant) 10/2018

Drug/Important Bio-Agent (IBA)

1	GalactosyltransferasesIBA 01/2023
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	Mifepristone (RU 486)FDA Link 01/2023
1	Misoprostol (Cytotec)FDA LinkGeneric 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Vitamin D FDA LinkGeneric 10/2018
1	Bevacizumab (Avastin)FDA Link 10/2018
1	25-hydroxyvitamin DIBA 10/2018
1	Panton-Valentine leukocidinIBA 03/2011

Therapy/Procedure

1	Blood Transfusion (Blood Transfusions) 01/2023
1	Curettage 01/2023